Fibroblast growth factor 1 - Phage Pharmaceuticals

Drug Profile

Fibroblast growth factor 1 - Phage Pharmaceuticals

Alternative Names: FGF-1 - Phage; Fibroblast growth factor 1 - Phage

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phage Pharmaceuticals
  • Class Anti-ischaemics; Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase Unknown Ear disorders
  • No development reported Wounds

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Wounds in USA
  • 21 Dec 2011 Investigation in Ear disorders in USA (unspecified route)
  • 21 Dec 2011 Phage Pharmaceuticals files an IND application with the FDA in US for Ear disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top